BioSpecifics Technologies Corp. Company Profile (NASDAQ:BSTC)

Analyst Ratings

Consensus Ratings for BioSpecifics Technologies Corp. (NASDAQ:BSTC) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $60.00 (48.48% upside)

Analysts' Ratings History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/16/2015MLV & Co.Initiated CoverageBuy$76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/23/2014AegisReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2014MKM PartnersBoost Price TargetBuy$38.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116$0.37$0.39$6.25 million$6.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q416$0.33$0.36$4.60 million$6.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$0.39$7.51 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215$0.44$0.24$2.60 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q414$0.32$2.30 million$5.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314$0.19$0.21$4.00 million$4.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214$0.12$0.09$2.91 million$2.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$0.07$0.12$2.46 million$2.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014$0.17$0.25ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3$0.04$0.17ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013$0.02$0.15ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013$0.18$0.19ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/18/2016Thomas WegmanMajor ShareholderSell50,000$33.01$1,650,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Toby WegmanDirectorSell25,000$33.01$825,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Thomas WegmanCEOSell2,000$50.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/23/2015Thomas WegmanCEOSell14,000$50.09$701,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Thomas WegmanCEOSell10,849$50.08$543,317.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Thomas WegmanCEOSell27,151$52.44$1,423,798.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Paul GitmanDirectorSell8,692$53.00$460,676.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Paul GitmanDirectorSell36,308$51.78$1,880,028.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2015Paul GitmanDirectorSell15,000$46.76$701,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Paul GitmanDirectorSell24,000$42.00$1,008,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Paul GitmanDirectorSell5,887$41.00$241,367.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Paul GitmanDirectorSell4,113$41.00$168,633.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Toby WegmanDirectorSell12,050$39.07$470,793.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Michael SchamrothDirectorSell5,200$39.20$203,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Thomas WegmanMajor ShareholderSell40,000$38.96$1,558,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Jeffrey Kenneth VogelInsiderSell88,329$27.43$2,422,864.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2014Paul GitmanDirectorSell10,000$28.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Henry MorganDirectorSell17,940$27.00$484,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Henry MorganDirectorSell2,060$27.01$55,640.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2014Henry MorganDirectorSell20,000$27.03$540,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Henry MorganDirectorSell20,000$25.84$516,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2014Paul GitmanDirectorSell10,000$25.00$250,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Paul GitmanDirectorSell15,000$23.00$345,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2013Paul GitmanDirectorSell5,000$20.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Henry MorganDirectorSell17,850$18.48$329,868.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Henry MorganDirectorSell2,150$18.35$39,452.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BioSpecifics Technologies Corp. (NASDAQ:BSTC)
DateHeadline
06/13/16 03:14 PMBioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
06/13/16 09:19 AMBioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human Lipoma - BioSpecifics Technologies Corp. (NASDAQ: BSTC) revealed Monday positive, statistically significant top-line results from its placebo-controlled, double-blind Phase II clinical study of collagenase clostridium histolyticum (CCH) for human lipoma treatment. According to the company, the study met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection, and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial. BioSpecifics President, Thomas Wegman, said, "We are pleased to report ...Full story available on Benzinga.com
06/03/16 12:09 PMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/31/16 03:00 PMBiospecifics Technologies (BSTC) Announces Publication of Data for Uterine Fibroid Treatment with CCH - Get your Free Trial here. BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and ...
05/31/16 02:04 PMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/31/16 06:52 AMBioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology - [at noodls] - LYNBROOK, N.Y., May 31, 2016/PRNewswire / -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first ...
05/31/16 06:31 AM7:31 am BioSpecifics Tech announces the publication of data on collagenase clostridium histolyticum for the treatment of uterine fibroids in the American Journal of Obstetrics & Gynecology -
05/27/16 04:03 PMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification -
05/26/16 06:23 PMETF’s with exposure to Biospecifics Technologies Corp. : May 26, 2016 -
05/25/16 12:02 PMBioSpecifics Technologies Corp (NASDAQ:BSTC) Closes At $35.13 - Investor Newswire - BioSpecifics Technologies Corp (NASDAQ:BSTC) Closes At $35.13Investor NewswireYesterday, the stock of BioSpecifics Technologies Corp (NASDAQ:BSTC) closed at $35.13 after opening at $35.22 and registering high of $36.33 and low of $35.06. The last price is $-35.74 off 1-year high of $72.07 and $5.63 away from low of $30.70 during ...Biospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 7.48% After Short CoveringWall Street Hints and Newsall 2 news articles »
05/24/16 12:31 PMBiospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 7.48% After Short Covering - Wall Street Hints and News - Biospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 7.48% After Short CoveringWall Street Hints and NewsThe short interest to Biospecifics Tech Corporation's float is 4.55%. The stock is up 1.41% or $0.49 after the news, hitting $35.56 per share. About 18,492 shares traded hands. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has declined 36.79% since ...and more »
05/24/16 12:31 PMBioSpecifics Technologies Corp (NASDAQ:BSTC) Quarterly EPS From Continuing Operations Stands At $0.4035 - Investor Newswire - BioSpecifics Technologies Corp (NASDAQ:BSTC) Quarterly EPS From Continuing Operations Stands At $0.4035Investor NewswireBioSpecifics Technologies Corp (NASDAQ:BSTC) diluted EPS from parent firm came at $1.3224 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it came at $1.3224. BioSpecifics Technologies Corp (NASDAQ:BSTC) posted net basic EPS of ...and more »
05/24/16 12:31 PMWegman Toby, Director of BioSpecifics Technologies Corp (NASDAQ:BSTC) sells 25,000 shares - According to BioSpecifics Technologies Corp's most recent Form 4 filing with the SEC dated May 19 11:42 AM, company Director, Wegman Toby disclosed selling 25,000 shares at a cost of $33.01. At the time of this transaction (May 18), this trade was worth $ ...
05/23/16 01:08 PMBiospecifics Technologies Corp. :BSTC-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/21/16 11:52 AMBioSpecifics Technologies Corp. (BSTC) is Trading Lower on Unusual Volume for May 18 - Equities.com - BioSpecifics Technologies Corp. (BSTC) is Trading Lower on Unusual Volume for May 18Equities.comBioSpecifics Technologies Corp. (BSTC) experienced unusually high volume on May. 18, as the stock lost 1.54% to a closing price of $33.79. The stock saw 146,171 shares trade hands over the course of the day on 1,170 trades. Given that the stock's ...and more »
05/21/16 11:52 AMRevenue Update on BioSpecifics Technologies Corp.(NASDAQ:BSTC) - Trade Calls - Revenue Update on BioSpecifics Technologies Corp.(NASDAQ:BSTC)Trade CallsBioSpecifics Technologies Corp.(NASDAQ:BSTC) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 10, 2016. Company reported revenue of $6.57M. Analysts estimated a revenue of $6.25M.Biospecifics Technologies Corp (BSTC) Files Form 4 Insider Selling : Toby Wegman Sells 25000 SharesMarket Digestall 2 news articles »
05/19/16 11:53 AMBiospecifics Tech Corporation (NASDAQ:BSTC) Short Interest Decreased By 7.48% - Wall Street Hints and News - Biospecifics Tech Corporation (NASDAQ:BSTC) Short Interest Decreased By 7.48%Wall Street Hints and NewsThe short interest to Biospecifics Tech Corporation's float is 4.55%. The stock decreased 1.54% or $0.53 during the last trading session, hitting $33.79. About 146,299 shares traded hands or 104.14% up from the average. BioSpecifics Technologies Corp.and more »
05/18/16 06:42 AMBioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference - [at noodls] - LYNBROOK, N.Y., May 18, 2016/PRNewswire / -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first ...
05/12/16 06:36 AMBioSpecifics Technologies Corp. (BSTC) Jumps 6.99% on May 10 - Equities.com - BioSpecifics Technologies Corp. (BSTC) Jumps 6.99% on May 10Equities.comBioSpecifics Technologies Corp. (BSTC) was among the biggest gainers on the Russell 2000 for Tuesday May 10 as the stock popped 6.99% to $37.64, representing a gain of $2.46 per share. Some 55,198 shares traded hands on 728 trades, compared with ...
05/12/16 06:36 AMBioSpecifics Technologies Corp. (NASDAQ:BSTC) Could Reverse on Topline Release - At market close on May 10, 2016, BioSpecifics Technologies Corp. (NASDAQ:BSTC) reported its first quarter, 2016, earnings. The company is down close to 10% on the announcement, and looks set to decline further across the Wednesday session in the US.
05/11/16 05:54 AMBioSpecifics Technologies Corp.: BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results - LYNBROOK, N.Y., May 10, 2016/PRNewswire / -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase ...
05/10/16 06:48 AMBioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results - [at noodls] - LYNBROOK, N.Y., May 10, 2016/PRNewswire / -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first ...
05/10/16 06:47 AMBIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement -
05/10/16 06:40 AMBioSpecifics posts 1Q profit -
05/10/16 06:07 AMQ1 2016 Biospecifics Technologies Corp Earnings Release - Before Market Open -
05/05/16 06:14 AMLatest Analyst Ratings For BioSpecifics Technologies Corp (BSTC) - Share Trading News - Latest Analyst Ratings For BioSpecifics Technologies Corp (BSTC)Share Trading News07/16/2015 – MLV & Co began new coverage on BioSpecifics Technologies Corp giving the company a “buy” rating. They now have a USD 76 price target on the stock. 12/23/2014 – BioSpecifics Technologies Corp had its “buy” rating reiterated by analysts at ...Biospecifics Tech Corporation (NASDAQ:BSTC) Shorted Shares Decreased By 2.41%Franklin Independentall 2 news articles »
05/03/16 07:10 AMBioSpecifics Technologies Corp. to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016 - [at noodls] - LYNBROOK, N.Y., May 3, 2016/PRNewswire / -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first ...
04/26/16 06:44 AMBioSpecifics Technologies Corp (NASDAQ:BSTC) Basic Consolidated EPS At $1.4087 - Investor Newswire - BioSpecifics Technologies Corp (NASDAQ:BSTC) Basic Consolidated EPS At $1.4087Investor NewswireFrom the parent firm, BioSpecifics Technologies Corp (NASDAQ:BSTC)'s diluted EPS was $1.3224 for the period ended 2015-12-31. The diluted per-share earnings from the parent firm for the quarterly period closed 2015-12-31 was $1.3224. BioSpecifics ...and more »
04/22/16 06:53 AMBioSpecifics Technologies Corp (BSTC) - Broker Update - Risers & Fallers - BioSpecifics Technologies Corp (BSTC) - Broker UpdateRisers & FallersThe Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an ...
04/22/16 06:53 AMBiospecifics Technology Corp.: Underfollowed And Undervalued - Seeking Alpha - Seeking AlphaBiospecifics Technology Corp.: Underfollowed And UndervaluedSeeking AlphaBiospecifics Technologies Corp. (NASDAQ:BSTC) is a microcap stock that trades on the NASDAQ. The company is in the biopharmaceutical sector and currently derives revenue from its product known as XIAFLEX in the United States, Canada and Australia, ...
04/22/16 06:53 AMBiospecifics Technology Corp.: Underfollowed And Undervalued - Not well covered by sell side analysts. Biospecifics Technologies Corp. (NASDAQ:BSTC) is a microcap stock that trades on the NASDAQ. The company is in the biopharmaceutical sector and currently derives revenue from its product known as XIAFLEX in the ...
04/17/16 05:54 AMBioSpecifics Technologies Corp. (BSTC) Jumps 5.67% on April 15 - Equities.com - Web Breaking NewsBioSpecifics Technologies Corp. (BSTC) Jumps 5.67% on April 15Equities.comBioSpecifics Technologies Corp. (BSTC) was among the biggest gainers on the Russell 2000 for Friday April 15 as the stock popped 5.67% to $36.90, representing a gain of $1.98 per share. Some 86,256 shares traded hands on 1,214 trades, compared with ...Biospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 6.16% After Short CoveringClinton FinancialBioSpecifics Technologies Corp. (BSTC) Shares Bought by Mutual of America Capital Management LLCWeb Breaking Newsall 3 news articles »
04/15/16 10:03 AMBioSpecifics Technologies Corp (BSTC) Updated Broker Price Targets - Share Trading News - BioSpecifics Technologies Corp (BSTC) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of BioSpecifics Technologies Corp (BSTC). The latest reports which are currently in issue on Friday 15th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/13/16 12:12 PMBioSpecifics Technologies Corp (BSTC) Latest Broker Coverage - Risers & Fallers - BioSpecifics Technologies Corp (BSTC) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of BioSpecifics Technologies Corp (BSTC). According to the latest broker reports outstanding on Tuesday 12th of April, 0 analysts have a rating of “strong buy”, 1 ...
04/12/16 10:09 AMBioSpecifics Technologies Corp (NASDAQ:BSTC)'s 52-Week Price Target At $60.00 - Investor Newswire - BioSpecifics Technologies Corp (NASDAQ:BSTC)'s 52-Week Price Target At $60.00Investor NewswireThomson Reuters completed its industry survey and following that it has given a 52-week price estimate of $60.00 to BioSpecifics Technologies Corp (NASDAQ:BSTC) stock. It is the average of the price estimates given by the brokerages during First Call ...and more »
04/12/16 10:09 AMBioSpecifics Technologies Corp (NASDAQ:BSTC) 50-Day Moving Average At $36.08 - Investor Newswire - BioSpecifics Technologies Corp (NASDAQ:BSTC) 50-Day Moving Average At $36.08Investor NewswireThe technical analysis of BioSpecifics Technologies Corp (NASDAQ:BSTC) stock highlights that it is trading $-0.28 points away -0.77% from its 50-day MA of $36.08. Further it is trading $-7.42 or -17.18% away its 200-day MA of $43.22. After considering ...
04/12/16 10:09 AMWhy BioSpecifics Technologies (BSTC) Stock Might be a Great Pick - One stock that might be an intriguing choice for investors right now is BioSpecifics Technologies Corporation (BSTC - Snapshot Report). This is because this security in the Medical-Drugs space is seeing solid earnings estimate revision activity ...
04/11/16 03:40 PMEdited Transcript of BSTC earnings conference call or presentation 14-Mar-16 12:30pm GMT -
04/09/16 09:23 AMCurrent Price Targets For BioSpecifics Technologies Corp (BSTC) - Risers & Fallers - Current Price Targets For BioSpecifics Technologies Corp (BSTC)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of BioSpecifics Technologies Corp (BSTC). The latest broker reports which are currently outstanding on Friday 8th of April state 0 analysts have a rating of “strong buy”, 1 ...
04/08/16 09:58 AMPalo Alto Investors Exits Position in BioSpecifics Technologies Corp. (BSTC) - Everything HUDSON - Palo Alto Investors Exits Position in BioSpecifics Technologies Corp. (BSTC)Everything HUDSONBioSpecifics Technologies Corp. (BSTC) : Palo Alto Investors has sold out all of its stake in BioSpecifics Technologies Corp. during the Q4 period, according to the information disclosed to the SEC. The investment management company has sold out 29,257 ...BioSpecifics Technologies Corp. (NASDAQ:BSTC) Given $60.00 Average Price Target by AnalystsThe Vista VoiceDoes BioSpecifics Technologies Corp. Have Any Gas After Today's Huge Decline?Stock Callerall 3 news articles »
04/07/16 10:36 AMBioSpecifics Technologies Corp. (BSTC) Jumps 9.56% on April 06 - Equities.com - BioSpecifics Technologies Corp. (BSTC) Jumps 9.56% on April 06Equities.comBioSpecifics Technologies Corp. (BSTC) was among the biggest gainers on the Russell 2000 for Wednesday April 06 as the stock popped 9.56% to $38.62, representing a gain of $3.37 per share. Some 222,151 shares traded hands on 2,170 trades, ...Biospecifics Tech Corporation (NASDAQ:BSTC) Sellers Covered 5.8% of Their ShortsClinton FinancialBIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) rated an average of Strong Buy by 1 of analystsHints News NetworkBioSpecifics Technologies Corp.'s Stock Is Sell After Forming Double Bottom Chart PatternStock CallerPR Newswire (press release)all 6 news articles »
04/06/16 12:01 PMBioSpecifics Technologies Corp. (BSTC) is Trading Lower on Unusual Volume for April 04 - Equities.com - BioSpecifics Technologies Corp. (BSTC) is Trading Lower on Unusual Volume for April 04Equities.comBioSpecifics Technologies Corp. (BSTC) experienced unusually high volume on Apr. 04, as the stock lost 2.35% to a closing price of $34.86. The stock saw 148,731 shares trade hands over the course of the day on 1,646 trades. Given that the stock's ...BioSpecifics Technologies Corp. to Present at the 15th Annual Needham Healthcare ConferencePR Newswire (press release)all 2 news articles »
04/06/16 07:30 AMBioSpecifics Technologies Corp. to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - LYNBROOK, N.Y., April 6, 2016/PRNewswire / -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first ...
04/05/16 11:33 AMAnalyst Coverage: BioSpecifics Technologies Corp (BSTC) - Risers & Fallers - Analyst Coverage: BioSpecifics Technologies Corp (BSTC)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of BioSpecifics Technologies Corp (BSTC). The latest broker reports which are currently outstanding on Tuesday 5th of April state 0 analysts have a rating of “strong buy”, ...Trader's Watch List: TransEnterix, Inc. (NYSEMKT:TRXC), BioSpecifics Technologies Corp. (NASDAQ:BSTC), 3D ...Benchmark Monitorall 2 news articles »
04/02/16 10:25 AMBIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC): Analysts Maintain an average rating of Strong Buy - Hints News Network - BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC): Analysts Maintain an average rating of Strong BuyHints News NetworkAnalysts have issued a 'Strong Buy' rating for BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC), according to data recently reviewed by Zacks. The company was rated a “Strong Buy” on average from the 1 analysts who currently cover the stock.Biospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 5.8% After Short CoveringSmallCapWired.comall 2 news articles »
04/01/16 11:54 AMBioSpecifics Technologies Corp (BSTC) Updated Broker Ratings - Risers & Fallers - BioSpecifics Technologies Corp (BSTC) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of BioSpecifics Technologies Corp (BSTC). According to the latest broker reports outstanding on Thursday 31st of March, 0 analysts have a rating of “strong buy”, 1 ...1 Analysts Rate BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) an Average of Strong BuyHints News NetworkHow did Rodman & Renshaw rate Biospecifics Technologies Corp.?The Duncan Independent (press release) (blog)all 6 news articles »
03/30/16 11:28 AMBioSpecifics Technologies Corp (BSTC) Short Interest Disclosure - SCSUCollegian - BioSpecifics Technologies Corp (BSTC) Short Interest DisclosureSCSUCollegianBioSpecifics Technologies Corp (NASDAQ:BSTC), A reduction of 16,858 shares or 5.8% was observed in the short interest of BioSpecifics Technologies Corp The interest on March 15,2016 came in at 274,397 shares and as per the average daily trading of ...After Last Week What Do Analysts Think Of BioSpecifics Technologies Corp (BSTC)Share Trading NewsBiospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 5.8% After Short CoveringStock CallerWhat are analysts saying about BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) earnings for next quarter?Hints News Networkall 4 news articles »
03/30/16 11:28 AMHatteras Funds adds BioSpecifics Technologies Corp. (BSTC) to its portfolio - Los Angeles Mirror - South Florida Hedge Fund ManagersHatteras Funds adds BioSpecifics Technologies Corp. (BSTC) to its portfolioLos Angeles MirrorBioSpecifics Technologies Corp. (BSTC) : Hatteras Funds added new position in BioSpecifics Technologies Corp. during the Fourth Quarter. The investment management firm now holds 22,740 shares of BioSpecifics Technologies Corp. which is valued at ...PNC Financial Services Group Inc. Has $3171000 Position in BioSpecifics Technologies Corp. (BSTC)South Florida Hedge Fund ManagersHot Stock List: Fabrinet (NYSE:FN), BioSpecifics Technologies Corp. (NASDAQ:BSTC), International Business ...KC Registerall 3 news articles »
03/29/16 01:43 PMAfter Last Week What Do Analysts Think Of BioSpecifics Technologies Corp (BSTC) - Share Trading News - After Last Week What Do Analysts Think Of BioSpecifics Technologies Corp (BSTC)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of BioSpecifics Technologies Corp (BSTC). According to data from Reuters, 0 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, ...BioSpecifics Technologies Corp (BSTC) Short Interest DisclosureSCSUCollegianWhat are analysts saying about BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) earnings for next quarter?Hints News NetworkBiospecifics Tech Corporation (NASDAQ:BSTC) Shorts Decreased by 5.8% After Short CoveringStock Callerall 4 news articles »
03/18/16 12:04 PMBIOSPECIFICS TECHNOLOGIES CORP Financials -

Social

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. logoBioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren's contracture and Peyronie's disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren's contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BSTC
  • CUSIP: 09093110
Key Metrics:
  • Previous Close: $40.41
  • 50 Day Moving Average: $39.55
  • 200 Day Moving Average: $37.12
  • P/E Ratio: 29.07
  • P/E Growth: 1.34
  • Market Cap: $283.64M
  • Beta: 1.35
  • Current Year EPS Consensus Estimate: $1.4 EPS
  • Next Year EPS Consensus Estimate: $1.62 EPS
Additional Links:
BioSpecifics Technologies Corp. (NASDAQ:BSTC) Chart for Wednesday, July, 27, 2016